Switching from intravenous to subcutaneous infliximab is safe and feasible in patients with perianal Crohn’s disease
Switching from IV to SC infliximab in CD with perianal lesions is safe and feasible.
Authors
- Clara Yzet (ORCID: https://orcid.org/0000-0001-7790-3919)
- Mathurin Fuméry (ORCID: https://orcid.org/0000-0002-2337-2902)
- Anthony Buisson (ORCID: https://orcid.org/0000-0002-6347-409X)
- Maria Nachury (ORCID: https://orcid.org/0000-0001-9583-8946)
- Dilek Çoban (ORCID: https://orcid.org/0000-0003-4598-3664)
- Pauline Wils
Institutions
- Inserm (FR)
- Université Clermont Auvergne (FR)
- Université de Lille (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Microbe, Intestine, Inflammation and Host Susceptibility (FR)
- Lille Inflammation Research International Center (FR)
- Hôpital Claude Huriez (FR)
- Périnatalité & Risques Toxiques (FR)
- Institute for Translational Research in Inflammation (FR)
- Université de Picardie Jules Verne (FR)
Publication Details
- Journal
- Therapeutic Advances in Gastroenterology
- Published
- 2025-03-22
- DOI
- https://doi.org/10.1177/17562848251326471
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82
Funders
- Celltrion Healthcare